Introduction to SNORA84, A Potential Drug Target (G100124534)

Target Name: SNORA84

NCBI ID: G100124534

SNORA84

Other Name(s): Small nucleolar RNA, H/ACA box 84 | small nucleolar RNA, H/ACA box 84

Introduction to SNORA84, A Potential Drug Target

In the realm of pharmaceuticals and diagnostics, identifying drug targets and biomarkers is crucial for the development of new therapies and improving patient outcomes. One such target that has gained significant attention is SNORA84, a non-coding RNA molecule with potential implications for a variety of diseases. This article aims to explore the role of SNORA84 as a drug target and biomarker, highlighting its significance and potential applications in the field of medicine.

Understanding SNORA84

SNORA84, also known as Small Nucleolar RNA, H/ACA Box 84, is a member of the small nucleolar RNA (snoRNA) family. snoRNAs are a class of non-coding RNA molecules primarily involved in the modification and processing of other RNA molecules. They play essential roles in cellular processes, such as ribosomal RNA (rRNA) pseudouridylation and alternative splicing of pre-mRNA. SNORA84, specifically, is classified as a small nucleolar RNA H/ACA box (snoRNA-H/ACA) and has its own distinct functions.

snoRNA-H/ACA Box

Within the snoRNA-H/ACA box class, SNORA84 plays a critical role in promoting pseudouridylation, a post-transcriptional modification of ribosomal RNA. Pseudouridylation enhances RNA structure stability and controls RNA-protein interactions. This specific snoRNA is implicated in catalyzing pseudouridines formation within specific regions of rRNA. By contributing to the structural integrity of rRNA, SNORA84 ensures optimal protein synthesis, which is fundamental for cellular homeostasis.

Implications in Disease

SNORA84 has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. Its aberrant expression or function in these disease contexts indicates its potential as a viable drug target or biomarker.

Cancer

In cancer, SNORA84 dysregulation has been observed in several studies. For instance, a study published in Nature Communications revealed that SNORA84 expression is significantly downregulated in breast cancer patients. Furthermore, restoring SNORA84 levels in cancer cells inhibited their proliferation and induced apoptosis through mechanisms yet to be fully elucidated. These findings suggest that SNORA84 may serve as a potential therapeutic target in breast cancer, offering new avenues for drug development.

Neurodegenerative Disorders

Emerging evidence has also linked SNORA84 to neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. A study published in Frontiers in Cellular Neuroscience identified SNORA84 as one of the differentially expressed snoRNAs in the brains of Parkinson's disease patients. Interestingly, SNORA84 was found to interact with genes associated with disease progression, providing insight into potential disease mechanisms. These findings highlight the potential utility of SNORA84 as a biomarker for neurodegenerative disorders, aiding in early diagnosis and disease monitoring.

Cardiovascular Conditions

Moreover, SNORA84 has been implicated in cardiovascular conditions, including heart failure and cardiac hypertrophy. In a study published in Cardiovascular Research, SNORA84 was identified as one of the snoRNAs associated with the regulation of cardiac gene expression. Targeting SNORA84 could potentially modulate gene expression patterns and thus impact cardiac function. Developing therapeutic strategies targeting SNORA84 may hold promise in treating cardiovascular diseases.

Therapeutic Potential

Considering SNORA84's involvement in various disease contexts, it represents an intriguing drug target with enormous therapeutic potential. By manipulating its expression or function, researchers may be able to modulate critical cellular processes and alleviate disease-related symptoms. However, further studies are necessary to elucidate the underlying mechanisms and maximize the clinical benefit offered by targeting SNORA84.

Biomarker Applications

Apart from being a drug target, SNORA84 also shows promise as a biomarker for disease diagnosis, prognosis, and monitoring treatment response. Analyzing SNORA84 expression levels in patient samples may provide valuable information about disease progression, therapeutic efficacy, and potential relapses. The development of sensitive and specific detection methods for SNORA84 could revolutionize diagnostic approaches, enabling early intervention, personalized treatment plans, and improved patient outcomes.

Conclusion

In conclusion, SNORA84, a snoRNA-H/ACA box, has emerged as a potential drug target and biomarker in various diseases. Its involvement in cancer, neurodegenerative disorders, and cardiovascular conditions highlights its versatility and impact on critical cellular processes. Targeting SNORA84 holds promise for therapeutic interventions, while its assessment as a biomarker offers potential advancements in disease diagnosis, prognosis, and treatment monitoring. Continued research into SNORA84's functions and interactions will undoubtedly uncover novel insights and drive the development of innovative therapeutic interventions in the future.

Protein Name: Small Nucleolar RNA, H/ACA Box 84

The "SNORA84 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA84 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets